KALA BIO, Inc.

Contributing Author

Recent Articles by KALA BIO, Inc.

Jan-05	KALA BIO Settles Approximately $10.6 million of Debt KALA GlobeNewswire
Dec-05	KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules KALA GlobeNewswire
Dec-04	KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules KALA GlobeNewswire
Dec-01	KALA BIO Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar KALA GlobeNewswire
Sep-29	KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint KALA GlobeNewswire
Sep-03	KALA BIO to Present at H.C. Wainwright 27th Annual Global Investment Conference KALA GlobeNewswire
Sep-02	KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director KALA GlobeNewswire
Aug-08	KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update KALA GlobeNewswire
Aug-06	KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference KALA GlobeNewswire
Jul-09	KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) KALA GlobeNewswire
Jul-07	KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) KALA GlobeNewswire
May-29	KALA BIO to Present at Jefferies Global Healthcare Conference KALA GlobeNewswire
May-14	KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update KALA GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.